Eckert & Ziegler opens the week with dividend adjustment, shares in SDAX focus
25.06.2026 - 19:32:30 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 19:31.
Eckert & Ziegler (DE0005659700) begins the new week on Xetra with its shares trading ex-dividend after the recent annual general meeting approved a higher payout for 2025, as shown in current SDAX price data and dividend notices from German platforms. The focus now shifts to how this higher dividend and the confirmed full-year guidance feed into analyst models for the radiopharmaceutical supplier.
What recent data points show
On German portals, Eckert & Ziegler is listed as an SDAX component, with the most recent indicated close around 15.5 euros, reflecting the adjustment for the dividend that is being detached at the start of this week based on earlier AGM resolutions for the 2025 financial year. Finanzen100 SDAX listing and dividend reference The share therefore opens the week in Frankfurt with a changed reference price, while the company continues to guide for rising earnings in 2026 after confirming its full-year outlook with first-quarter figures in May.
MarketScreener’s company overview still highlights the May 14 dividend announcement for Eckert & Ziegler, with the payment scheduled for late June and a yield calculated on the then-prevailing share price, illustrating the income component now reflected in the ex-dividend quotation. MarketScreener dividend overview and news list In May, the company also reiterated its guidance for the current year alongside reporting first-quarter sales of around 72.9 million euros, underlining management’s expectations of continued operational progress.
Analyst consensus on the shares
According to consensus data compiled by MarketScreener, Eckert & Ziegler currently shows an average target price of roughly 22.10 euros per share, significantly above the latest indicated SDAX trading level around the mid-teens, based on a set of analyst estimates updated through the spring reporting period. MarketScreener consensus and price-target overview The distribution of ratings on that platform is tilted towards positive recommendations, reflecting the market’s view on the company’s niche in radiopharmaceuticals and isotope technology.
In April, Metzler reiterated a Buy stance on Eckert & Ziegler and highlighted the stock’s appeal after a period of weaker price performance, using the confirmed guidance and regulatory progress as arguments in favor of the investment case, according to the German press summaries embedded in the same consensus pages. Analyst rating breakdown with Metzler reference This forms part of a broader analyst narrative which emphasizes the company’s exposure to growing demand for nuclear medicine applications while also noting execution risks in expansion projects.
All news and analysis on the Eckert & Ziegler shares
Further corporate releases, price data and background reports on Eckert & Ziegler are collected in the dedicated topic area and on the company’s own investor-relations pages.
The business behind the stock
Eckert & Ziegler generates its revenue primarily with radioactive components and services for medical and industrial applications, including sealed sources for brachytherapy and radiopharmaceuticals used in cancer diagnostics and therapy, as summarized in its public company materials. In recent quarters, management emphasized growth in nuclear medicine products, where isotopes for targeted therapies and imaging underpin long-term demand trends that are central for analyst valuation models.
Where the stock trades today
The Eckert & Ziegler shares (DE0005659700) most recently traded on Xetra at around 15.6 euros, according to late-June price data from German exchanges, with this level serving as the current reference point for SDAX investors monitoring the stock.
Key data on the Eckert & Ziegler shares
- Company: Eckert & Ziegler SE
- ISIN: DE0005659700
- WKN: 565970
- Ticker: EUZ
- Trading venue: Xetra
- Price (as of 2026-06-25, 17:20): 15.6 EUR
- Market cap: 800 million EUR (as of 2026-06-25)
- Sector / industry: Health Care / Biotechnology & Medical Technology
- Index membership: SDAX
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Historical data and analyst estimates do not guarantee future performance. Readers should conduct their own research before making investment decisions.
